Company Overview - RxSight is focused on transforming cataract surgery outcomes through a new capability called adjustability, which has not previously existed in ophthalmology [2] - The company has grown to approximately 500 employees and has performed around 300,000 Light Adjustable Lens (LAL) procedures [3] Market Position - RxSight operates in about 1,100 ophthalmic offices and has trained over 2,500 surgeons [3] - The company has achieved a market share of approximately 10% in the U.S. premium intraocular lens (IOL) market [3] Recent Performance - RxSight reported a 12% year-over-year growth in procedures and a nearly 20% increase in its installed base [4] - The company announced the appointment of a new Chief Financial Officer, Mark Wilterding, who brings extensive experience in med tech and banking [4]

Summary of RxSight FY Conference Call (January 13, 2026) Company Overview - **Company**: RxSight (NasdaqGM:RXST) - **Industry**: MedTech, specifically focusing on ophthalmology and cataract surgery - **Key Product**: Light Adjustable Lens (LAL), a premium intraocular lens (IOL) that allows for post-operative adjustments to improve visual outcomes Core Points and Arguments - **Growth Metrics**: - RxSight has grown to approximately 500 employees and performed around 300,000 LAL procedures - The company has a market share of about 10% in the U.S. premium IOL market [4][39] - Achieved 12% year-over-year growth in procedures and nearly 20% increase in installed base [5][13] - **Market Dynamics**: - The U.S. sees about 5 million cataract surgeries annually, with a shift towards premium IOLs that offer enhanced services for patients willing to pay extra [7][8] - The premium IOL market is characterized by two main types: toric (astigmatism-correcting) and presbyopia-correcting lenses [8] - **Adjustability Technology**: - Introduced the concept of adjustability in cataract surgery, allowing for personalized lens adjustments post-surgery [9][10] - Over 90% of patients report high refractive accuracy with LAL, and 90% of doctors believe it provides the highest quality of vision [11][12] - **Financial Performance**: - Pre-announced fourth-quarter sales at $32.6 million, exceeding expectations [18] - Each LAL procedure generates approximately $2,000 in additional revenue for practices [12] - **Future Growth Strategies**: - Focus on increasing same-store sales and expanding the number of surgeons using LAL technology [13][19] - Plans to place more Light Delivery Devices (LDD) in additional practices, currently servicing only 25% of U.S. cataract surgeons [13][14] - **International Expansion**: - The company is targeting major markets in Asia and Europe, where 80% of premium procedures occur [15][42] - Initial commercialization efforts have begun in countries like Korea and Canada, with plans for further expansion [43][44] - **Market Positioning**: - RxSight is positioned as the third largest premium IOL provider in the U.S., with a long runway for growth [37] - The company believes adjustability will become a dominant feature in the premium IOL market, despite potential competition [40][41] Additional Important Insights - **Operational Challenges**: - The rapid growth led to some operational challenges in supporting a large installed base, which the company is addressing through improved customer support and training [28][30] - **Cash Position**: - Ended the year with approximately $225 million in cash, providing a strong financial position to support growth initiatives [47] - **Reimbursement Landscape**: - While the cost-effectiveness of LAL is favorable, expanding reimbursement from Medicare and insurers for cataract procedures is unlikely [52][53] This summary encapsulates the key points discussed during the conference call, highlighting RxSight's growth, market dynamics, and strategic initiatives moving forward.

RxSight, Inc. (RXST) shares ended the last trading session 14.1% higher at $10.09. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 30% loss over the past four weeks.RxSight scored a strong price increase, driven by investor optimism surrounding the release of its preliminary unaudited financial and operational results for the fourth quarter and full-year 2025. The company also announced that veteran Mark Wilterding ...

Investor Presentation January 2026 This presentation contains forward-looking statements within the meaning of the Private Securities litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are considered forward-looking statements, which are usually identified by the use of words such as "anticipates," believes," "continues," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," " projects," "seeks," "should," "will," "forecas ...

Financial Results - On January 11, 2026, RxSight, Inc. announced preliminary unaudited financial results for Q4 and full-year 2025[6]. - The financial results announcement is not deemed "filed" under the Exchange Act[7]. - The press release is attached as Exhibit 99.1 for further details on the financial results[17]. Executive Appointment - The company appointed Mark Wilterding as Chief Financial Officer effective January 11, 2026, replacing Shelley Thunen[8]. - The press release regarding Mr. Wilterding's appointment was issued on January 11, 2026[15]. Compensation Details - Mr. Wilterding's annual base salary is set at $550,000, with an annual bonus potential of up to 65% of his base salary[10]. - Mr. Wilterding received options to purchase 258,770 shares of common stock and an award of 163,528 restricted stock units[11]. Company Classification - The company is not classified as an emerging growth company under the Securities Act[5]. - The company operates under the Nasdaq Stock Market LLC with the symbol RXST[5]. - The company is expected to file the full text of the Employment Agreement and Severance Agreement in a subsequent periodic report[14].

Core Viewpoint - RxSight, Inc. has announced preliminary unaudited financial and operational results for Q4 and full-year 2025, indicating a positive trajectory in patient treatment and market share despite challenges faced during the year [1][3][8]. Financial Results - Preliminary unaudited revenue for Q4 2025 is expected to be approximately $32.6 million, driven by the sale of 28,611 Light Adjustable Lenses (LAL™/LAL+®), representing a 10% increase in procedure volume compared to Q3 2025 [8]. - Preliminary unaudited revenue for the full year 2025 is expected to be approximately $134.5 million, exceeding previous guidance of $125 to $130 million, with a 12% increase in procedure volume compared to 2024 [8]. - The company installed 1,134 Light Delivery Devices (LDDs) by the end of 2025, with a total of 163 LDDs sold during the year [8]. Market Position and Growth - RxSight holds approximately 10% market share in the premium intraocular lens (IOL) market, with adoption by over 25% of U.S. cataract surgeons [3]. - The company has made significant progress in treating more patients than ever before, positioning itself for sustained long-term growth [3]. Leadership Transition - Mark Wilterding has been appointed as the new Chief Financial Officer, effective January 11, 2026, bringing over 25 years of financial leadership experience [4][5]. - Wilterding's previous role was Senior Vice President of Global Finance for Edwards Lifesciences, where he oversaw various financial operations [5]. Future Outlook - The company is set to announce audited full-year 2025 financial results and guidance for 2026 in February 2026 [7][8].

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving RxSight, Inc. and its executives [1] Group 1: Management Changes - RxSight announced the departure of its Chief Financial Officer, Shelley Thunen, who will remain until her successor is appointed or by January 31, 2026 [2] - The departure of Thunen was noted as surprising by financial services firm BTIG, especially given early signs of operational improvement and a recent management reshuffle [2] - The timing of these leadership transitions suggests ongoing commercial challenges for RxSight, potentially delaying a broader recovery into 2026 despite some recent progress [2] Group 2: Stock Performance - Following the announcement of Thunen's departure, RxSight's stock price fell by $1.22 per share, representing a decline of 9.98%, closing at $11.01 per share on December 23, 2025 [3]

Core Insights - RxSight, Inc. announced the transition of Shelley Thunen from her role as Chief Financial Officer, effective until the appointment of her successor or January 31, 2026 [1] - Thunen will continue to support the company as a consultant after her transition [1] Group 1: Company Overview - RxSight, Inc. is focused on providing high-quality customized vision to patients following cataract surgery [3] - The company’s flagship product, the RxSight Light Adjustable Lens system, is the first and only commercially available intraocular lens technology that can be adjusted post-surgery [3] Group 2: Leadership Impact - Thunen has played a crucial role in RxSight's development, helping the company grow from a pre-commercial stage to having over 1,100 Light Delivery Devices (LDDs) in the field and performing over a quarter million procedures [2] - Her leadership was instrumental during significant milestones, including the company's initial public offering in 2021 [2]

Summary of RxSight Conference Call Company Overview - **Company**: RxSight - **Event**: 2025 Piper Sandler Healthcare Conference - **Management Team Present**: Ron Kurtz (President and CEO), Shelley Thunen (CFO), Oliver (Investor Relations) Industry Context - **Industry**: Cataract surgery and premium intraocular lenses (IOLs) - **Market Size**: The premium IOL market is projected to be around $26 billion to $27 billion globally, with significant growth opportunities in international markets [29][32] Key Challenges and Market Dynamics - **Market Contraction**: The general cataract market contracted early in 2025, which is unusual, but has since normalized [4] - **Increased Competition**: Several competitive IOLs were introduced in the premium space, impacting market dynamics. Major players launched new presbyopia-correcting IOLs, leading to enhanced marketing efforts [4][5] - **Adoption Focus**: The company is concentrating on the adoption of its differentiated LAL technology, which currently represents about 10% of the premium IOL space, up from zero a few years ago [6] Financial Guidance and Performance - **Q4 Guidance**: The company anticipates a sequential revenue step down in Q4, which is typically its strongest quarter. Q3 performance exceeded expectations, particularly in LDD sales [7][9] - **2026 Revenue Expectations**: The company has not provided specific guidance for 2026 but expects sequential growth quarter over quarter, with a street estimate of $135 million, representing a 5% year-over-year growth [11][12] Competitive Landscape - **Market Positioning**: The company believes it has a unique position in the premium IOL market, with no direct competition for its LAL technology in the near term [16][17] - **Future Competitors**: While new entrants are expected, they are not anticipated to significantly impact RxSight's market share in the immediate future [14] Sales and Commercial Strategy - **Sales Force Alignment**: The company has aligned its sales and clinical teams to enhance same-store sales growth and utilization of LAL technology [20][21] - **Training and Adoption**: Efforts are focused on training physicians and addressing pushback against adopting LAL technology, emphasizing the clinical outcomes and return on investment [23][25] International Expansion - **International Strategy**: The company has hired a VP of International and is focusing on expanding its presence in Europe and Asia, with recent approvals in the EU and several Asian countries [29][30] - **Market Potential**: The international markets represent a significant growth opportunity, potentially doubling the U.S. market size [32] Financial Metrics - **Gross Margin Insights**: The company reported a high gross margin in Q3, driven by LAL sales, but does not expect this level to be sustainable. Gross margin is influenced by product mix and production volume [38] - **Operational Expenses**: The company is cautious with OpEx but is investing in sales, marketing, and R&D to drive future growth [39] Conclusion - RxSight is navigating a challenging market environment with increased competition and a focus on technology adoption. The company is strategically positioning itself for growth in both domestic and international markets while managing operational efficiencies and financial performance.

Core Insights - RxSight, Inc. is an ophthalmic medical device company focused on providing customized vision solutions for patients post-cataract surgery [3] - The company will participate in the Piper Sandler 37th Annual Healthcare Conference in New York City on December 3, 2025 [1][2] Company Overview - RxSight offers the RxSight Light Adjustable Lens system, which includes the Light Adjustable Lens (LAL/LAL+), Light Delivery Device (LDD™), and accessories, representing the first adjustable intraocular lens technology available commercially [3] - This technology allows for post-surgery adjustments, enabling healthcare providers to tailor vision outcomes for patients [3] Event Participation - Management is scheduled to present at the conference on December 3, 2025, at 12:00 p.m. Eastern Time, with a live and archived webcast available for investors [2]